TY - JOUR
T1 - CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
AU - Zhao-Fleming, Hannah H.
AU - Valencia Sanchez, Cristina
AU - Sechi, Elia
AU - Inbarasu, Jery
AU - Wijdicks, Eelco F.
AU - Pittock, Sean J.
AU - Chen, John J.
AU - Wingerchuk, Dean M.
AU - Weinshenker, Brian G.
AU - Lopez-Chiriboga, Sebastian
AU - Dubey, Divyanshu
AU - Tillema, Jan Mendelt
AU - Toledano, Michel
AU - Yadav, Hemang
AU - Flanagan, Eoin P.
N1 - Funding Information:
This study was funded by an RO1 from the National Institute of Neurologic Disorders and Stroke (R01NS113828). The authors also acknowledge the Guthy Jackson Foundation for its support.
Funding Information:
H.H. Zhao-Fleming, C. Valencia Sanchez, E. Sechi, and J. Inbarasu report no disclosures. E.F. Wijdicks reports no disclosures other than royalties for books with Oxford University Press. S.J. Pittock reports grants, personal fees, and nonfinancial support from Alexion Pharmaceuticals, Inc; grants, personal fees, nonfinancial support, and other support from MedImmune, Inc/Viela Bio; and personal fees for consulting from Genentech/Roche. He has a patent, patent No. 8,889,102 (application No. 12-678350, Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia), issued and a patent, patent No. 9,891,219B2 (application 12-573942, Methods for Treating Neuromyelitis Optica [NMO] by Administration of Eculizumab to an Individual That is Aquaporin-4 (AQP4)-IgG Autoantibody Positive), issued. J.J. Chen reports no disclosures. D.M. Wingerchuk reports receiving consulting fees from Genentech, Roche, Biogen, Novartis, TG Therapeutics, Third Rock Ventures, Reistone, and Mitsubuishi Tanabe; serving as member of a clinical trial adjudication committee for VielaBio; and receiving research funds paid to Mayo Clinic from Alexion and TerumoBCT. B.G. Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders. He serves as a member of an adjudication committee for clinical trials in NMO conducted by VielaBio and Alexion . He is a consultant for Chugai, Roche, Genentech, and Mitsubishi Tanabe regarding clinical trials for NMO. S. Lopez-Chiriboga, D. Dubey, J.-M. Tillema, M. Toledano, and H. Yadav report no disclosures. E.P. Flanagan has served on advisory boards for Alexion, Genentech, and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times, royalties from UpToDate. He was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. He has received funding from the NIH (R01NS113828), is a member of the medical advisory board of the MOG project and an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
Copyright 2021 American Academy of Neurology.
PY - 2021/9/28
Y1 - 2021/9/28
N2 - Background and ObjectiveSevere attacks of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for MOGAD. We sought to compare the frequency, characteristics, and outcomes of MOGAD and AQP4-NMOSD attacks requiring ventilatory support.MethodsThis retrospective descriptive study identified Mayo Clinic patients (January 1, 1996-December 1, 2020) with MOGAD or AQP4-NMOSD and an attack requiring noninvasive or invasive ventilation at Mayo Clinic or an outside facility by searching for relevant terms in their electronic medical record. Inclusion criteria were (1) attack-related requirement for noninvasive (bilevel positive airway pressure or continuous positive airway pressure) or invasive respiratory support (mechanical ventilation); (2) MOG or AQP4 antibody positivity with fulfillment of MOGAD and AQP4-NMOSD clinical diagnostic criteria, respectively; and (3) sufficient clinical details. We collected data on demographics, comorbid conditions, indication for and duration of respiratory support, MRI findings, treatments, and outcomes. The races of those with attacks requiring respiratory support were compared to those without such attacks in MOGAD and AQP4-NMOSD.ResultsAttacks requiring ventilatory support were similarly rare in patients with MOGAD (8 of 279, 2.9%) and AQP4-NMOSD (11 of 503 [2.2%]) (p = 0.63). The age at attack (median years [range]) (MOGAD 31.5 [5-47] vs AQP4-NMOSD 43 [14-65]; p = 0.01) and percentage of female sex (MOGAD 3 of 8 [38%] vs AQP4-NMOSD 10 of 11 [91%]; p = 0.04) differed. The reasons for ventilation differed between MOGAD (inability to protect airway from seizure, encephalitis or encephalomyelitis with attacks of acute disseminated encephalomyelitis 5 [62.5%] or unilateral cortical encephalitis 3 [37.5%]) and AQP4-NMOSD (inability to protect airway from cervical myelitis 9 [82%], rhombencephalitis 1 [9%], or combinations of both 1 [9%]). Median ventilation duration for MOGAD was 2 days (range 1-7 days) vs 19 days (range 6-330 days) for AQP4-NMOSD (p = 0.01). All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack. For AQP4-NMOSD, Black race was overrepresented for attacks requiring ventilatory support vs those without these episodes (5 of 11 [45%] vs 88 of 457 [19%]; p = 0.045).DiscussionVentilatory support is rarely required for MOGAD and AQP4-NMOSD attacks, and the indications differ. Compared to MOGAD, these attacks in AQP4-NMOSD may have higher morbidity and mortality, and those of Black race were more predisposed, which we suspect may relate to socially mediated health inequality.
AB - Background and ObjectiveSevere attacks of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for MOGAD. We sought to compare the frequency, characteristics, and outcomes of MOGAD and AQP4-NMOSD attacks requiring ventilatory support.MethodsThis retrospective descriptive study identified Mayo Clinic patients (January 1, 1996-December 1, 2020) with MOGAD or AQP4-NMOSD and an attack requiring noninvasive or invasive ventilation at Mayo Clinic or an outside facility by searching for relevant terms in their electronic medical record. Inclusion criteria were (1) attack-related requirement for noninvasive (bilevel positive airway pressure or continuous positive airway pressure) or invasive respiratory support (mechanical ventilation); (2) MOG or AQP4 antibody positivity with fulfillment of MOGAD and AQP4-NMOSD clinical diagnostic criteria, respectively; and (3) sufficient clinical details. We collected data on demographics, comorbid conditions, indication for and duration of respiratory support, MRI findings, treatments, and outcomes. The races of those with attacks requiring respiratory support were compared to those without such attacks in MOGAD and AQP4-NMOSD.ResultsAttacks requiring ventilatory support were similarly rare in patients with MOGAD (8 of 279, 2.9%) and AQP4-NMOSD (11 of 503 [2.2%]) (p = 0.63). The age at attack (median years [range]) (MOGAD 31.5 [5-47] vs AQP4-NMOSD 43 [14-65]; p = 0.01) and percentage of female sex (MOGAD 3 of 8 [38%] vs AQP4-NMOSD 10 of 11 [91%]; p = 0.04) differed. The reasons for ventilation differed between MOGAD (inability to protect airway from seizure, encephalitis or encephalomyelitis with attacks of acute disseminated encephalomyelitis 5 [62.5%] or unilateral cortical encephalitis 3 [37.5%]) and AQP4-NMOSD (inability to protect airway from cervical myelitis 9 [82%], rhombencephalitis 1 [9%], or combinations of both 1 [9%]). Median ventilation duration for MOGAD was 2 days (range 1-7 days) vs 19 days (range 6-330 days) for AQP4-NMOSD (p = 0.01). All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack. For AQP4-NMOSD, Black race was overrepresented for attacks requiring ventilatory support vs those without these episodes (5 of 11 [45%] vs 88 of 457 [19%]; p = 0.045).DiscussionVentilatory support is rarely required for MOGAD and AQP4-NMOSD attacks, and the indications differ. Compared to MOGAD, these attacks in AQP4-NMOSD may have higher morbidity and mortality, and those of Black race were more predisposed, which we suspect may relate to socially mediated health inequality.
UR - http://www.scopus.com/inward/record.url?scp=85117740167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117740167&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000012599
DO - 10.1212/WNL.0000000000012599
M3 - Article
C2 - 34389648
AN - SCOPUS:85117740167
SN - 0028-3878
VL - 97
SP - E1351-E1358
JO - Neurology
JF - Neurology
IS - 13
ER -